Robert Davis; Chairman of the Board, President, Chief Executive Officer; Merck & Co Inc Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive ...

Shareholders might have noticed that Merck & Co., Inc. (NYSE:MRK) filed its yearly result this time last week. The early response was not positive, with shares down 8.8% to US$89.67 in the past week.

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best cancer stocks to buy. Cancer is the second leading cause of death across the globe ...

(see more details here). Merck & Co., Inc. (NYSE:MRK) is an American pharmaceutical company, headquartered in New Jersey. The company mainly offers innovative health solutions to its consumers.

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

RAHWAY, N.J. (AP) — RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had ...

(RTTNews) - Below are the earnings highlights for Merck & Co Inc. (MRK): Earnings: $3.743 billion in Q4 vs. -$1.226 billion in the same period last year. EPS: $1.48 in Q4 vs. -$0.48 in the same ...

file photo shows Merck corporate headquarters in Kenilworth, N.J. RAHWAY, N.J. – Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

Merck & Co Inc (Symbol: MRK) presently has a stellar rank, in the top 10% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...